On November 11, Humana rose 3.19% in Regular Trading, trading at $436.06 per share, with turnover of $127 million.
The latest identifiable catalyst was a fresh analyst action: Jefferies raised its price target on Humana to $520 from $420, following a broader wave of forecast increases after the company’s recent third-quarter results.
Earlier, Humana reported a third-quarter adjusted loss of $0.70 per share on revenue of $41.16 billion, both better than consensus expectations for a $1.00 loss and $40.87 billion in revenue. The company also raised its adjusted EPS guidance for 2026 to at least $9.50 from at least $9.00, above the $9.16 consensus view. Additional post-results target increases included $526 from Piper Sandler and analyst forecasts rising into a $495 to $587 range, reinforcing a more constructive valuation backdrop for the managed-care insurer.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments